10x Genomics Unveils Preliminary Financials for FY 2024
10x Genomics, Inc. (Nasdaq: TXG), recognized as a frontrunner in single-cell and spatial biology solutions, has recently disclosed its preliminary and unaudited results for the fourth quarter and full fiscal year of 2024. This announcement underscores the company's resilience and commitment to innovation in the life sciences sector.
Impressive Revenue Growth Highlights
10x Genomics reported an estimated revenue of approximately $611 million for FY 2024, with Q4 contributing around $165 million. This represents a 9% sequential growth, showcasing the company's adaptability amidst a competitive landscape.
Fourth Quarter Results Breakdown
In Q4 2024, the revenue figures revealed a year-over-year insight that shows modest sequential gains yet a slight decrease compared to the previous year. Instruments revenue stood at about $24.4 million, indicating a significant sequential growth of 28%, although it saw a stark year-over-year decline of 37%. This segment consists of about $10.9 million from Chromium instruments and $13.4 million from Spatial instruments. Meanwhile, consumables generated an estimated $133.5 million, reflecting a 6% sequential growth and a 5% decrease from the same quarter last year.
Full Year Financial Overview
For the entire year, 10x Genomics recorded approximately $610.8 million in revenue, slightly down by 1% compared to the previous year. Breaking this down further, instruments revenue accounted for about $92.7 million. Although this showed a drop of 25% from the prior year, consumables revenue was a bright spot, crossing $493.4 million - a 3% increase year-over-year. Additionally, services revenue witnessed remarkable growth of 57%, totaling around $24.6 million.
Strategic Developments and Future Outlook
As of the end of 2024, 10x Genomics has sold over 7,000 instruments, marking a significant achievement. This total includes more than 5,800 Chromium instruments, over 800 Visium instruments, and around 400 Xenium instruments, further solidifying the company’s position in the marketplace.
Serge Saxonov, Co-founder and CEO of 10x Genomics, expressed optimism about the company’s direction, stating, "Our team delivered solid sequential revenue growth over last quarter. We are confident the work we've done throughout 2024 sets us up well for the future and better positions us to deliver on the full promise of single cell and spatial biology." His insights reflect a confident outlook aimed at addressing the complexities of biological research.
Upcoming Events
10x Genomics will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January. This engagement will offer valuable insights into the company’s strategic initiatives and performance outlook for the coming year, alongside presentations aimed at investors and industry stakeholders.
Understanding 10x Genomics' Innovations
The company is not just focused on current revenues but aims to further enhance its dedicated efforts towards advancing human health through its innovative solutions. Their instruments, consumables, and software for genomic coverage continue to cater to diverse applications in fields such as oncology, immunology, and neuroscience.
Commitment to Transparency
It's important to note that the results shared are preliminary and subject to further adjustments as the company finalizes its year-end reports. 10x Genomics emphasizes its commitment to maintaining transparency with its stakeholders throughout this process.
Frequently Asked Questions
What were the total revenues for 10x Genomics in FY 2024?
The total revenue for 10x Genomics in FY 2024 was approximately $611 million, with Q4 revenue around $165 million.
How did the revenue for instruments perform in Q4 2024?
In Q4 2024, the instruments revenue was approximately $24.4 million, reflecting a sequential growth of 28% but a 37% decline compared to the previous year's Q4.
What is the outlook for 10x Genomics in the upcoming year?
10x Genomics is optimistic about its future, indicating that the groundwork laid in 2024 positions them well to harness the potential of single-cell and spatial biology.
How many instruments has 10x Genomics sold as of 2024?
As of the end of 2024, 10x Genomics has sold over 7,000 instruments, including over 5,800 Chromium instruments.
What sectors are benefiting from 10x Genomics innovations?
10x Genomics' innovations primarily benefit sectors such as oncology, immunology, and neuroscience, aiding in groundbreaking research developments.
